Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing

19Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

The incidence of allergic disease has grown tremendously in the past three generations. While current treatments are effective for some, there is considerable unmet need. Mast cells are critical effectors of allergic inflammation. Their secreted mediators and the receptors for these mediators have long been the target of allergy therapy. Recent drugs have moved a step earlier in mast cell activation, blocking IgE, IL-4, and IL-13 interactions with their receptors. In this review, we summarize the latest therapies targeting mast cells as well as new drugs in clinical trials. In addition, we offer support for repurposing FDA-approved drugs to target mast cells in new ways. With a multitude of highly selective drugs available for cancer, autoimmunity, and metabolic disorders, drug repurposing offers optimism for the future of allergy therapy.

Cite

CITATION STYLE

APA

Burchett, J. R., Dailey, J. M., Kee, S. A., Pryor, D. T., Kotha, A., Kankaria, R. A., … Ryan, J. J. (2022, October 1). Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. Cells. MDPI. https://doi.org/10.3390/cells11193031

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free